Evidence map›Paper›PMID 41809978›Full record

ArticleJHLT open2026

Mapping acute lung allograft dysfunction of unknown cause after lung transplantation: Insights from clinical and radiological patterns.

Marco Guerrieri, Matteo Fanetti, Felice Perillo, Chiara Piscitello, Francesco Gentili, Vito Di Martino, Armando Perrella, Jean-Guillaume Starnini, Cristiana Bellan, Luca Luzzi and 6 more

Abstract read
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marco GuerrieriRespiratory Diseases Unit, University Hospital of Siena, Siena, Italy.
Matteo FanettiRespiratory Diseases Unit, University Hospital of Siena, Siena, Italy.
Felice PerilloRespiratory Diseases Unit, University Hospital of Siena, Siena, Italy.
Chiara PiscitelloImaging Diagnostic, University Hospital of Siena, Siena, Italy.
Francesco GentiliImaging Diagnostic, University Hospital of Siena, Siena, Italy.
Vito Di MartinoImaging Diagnostic, University Hospital of Siena, Siena, Italy.
Armando PerrellaImaging Diagnostic, University Hospital of Siena, Siena, Italy.
Jean-Guillaume StarniniRespiratory Diseases Unit, University Hospital of Siena, Siena, Italy.
Cristiana BellanAnatomy Pathology Unit, University Hospital of Siena, Siena, Italy.
Luca LuzziThoracic Surgery, University Hospital of Siena, Siena, Italy.
Chiara CatelliThoracic Surgery, University Hospital of Siena, Siena, Italy.
Federico FranchiCardiothoracic and Vascular Anesthesia and Intensive Care Unit, University Hospital of Siena, Siena, Italy.
Antonella FossiRespiratory Diseases Unit, University Hospital of Siena, Siena, Italy.
Elena BargagliRespiratory Diseases Unit, University Hospital of Siena, Siena, Italy.
Maria Antonietta MazzeiImaging Diagnostic, University Hospital of Siena, Siena, Italy.
David BennettRespiratory Diseases Unit, University Hospital of Siena, Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute lung allograft dysfunction (ALAD) is a recently defined post-transplant clinical entity characterized by acute, potentially reversible graft dysfunction. The aim of this study was to describe the clinical and radiological features of ALAD in which no identifiable underlying cause could be recognized, hereafter referred to as idiopathic ALAD (i-ALAD). Methods: Among all bronchoscopies with bronchoalveolar lavage and transbronchial lung biopsy performed in a single-center cohort of lung transplant recipients between 2013 and 2024 ( Results: Among 158 lung transplant recipients, 20 cases of i-ALAD were identified, corresponding to an incidence of 12.4%. ALAD was reversible in most patients, although 2 progressed to chronic lung allograft dysfunction (CLAD). Six patients (30%) met criteria for baseline lung allograft dysfunction (BLAD), and 6 had a history of recurrent ACR. HRCT most frequently demonstrated bronchial wall thickening (85%), smooth interlobular septal thickening, and pulmonary micronodules (80%), with characteristic lobar distribution patterns. Compared with ACR, i-ALAD was associated with a significantly higher prevalence of bronchiectasis/bronchiolectasis, air trapping, and pleural effusion. Conclusions: ALAD is a relatively frequent and potentially reversible complication after lung transplantation but may represent a risk factor for subsequent CLAD development. Distinctive HRCT features may assist in identifying ALAD of unknown cause and stratifying patients according to the risk of disease progression. Prospective, multicenter studies are warranted to validate these findings and further refine the clinical and radiological characterization of i-ALAD.

Indexed as

Acute lung allograft dysfunctionFollow-upHigh-resolution chest CTLung transplantPost-transplant complications

Identifiers

PMID41809978
PMCPMC12969387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.